Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban for Cirrhotic Patients With Variceal Bleeding and Portal Vein Thrombosis
NCT07602062Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of rivaroxaban in portal vein thrombosis (PVT) and Variceal bleeding (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Adverse Events at 6 months. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
rivaroxaban
03
Conditions
portal vein thrombosis (PVT)Variceal bleeding
Beyond the preview
Go deeper on NCT07602062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07602062.